← boardnext 2027-05-30next 2027-12-31
OLMA
Olema Pharmaceuticals, Inc.distress 4/10 · elevated risk$11.33-1%today-68% from 52w high
Oncology 2
Lead: ER+/HER2- metastatic breast cancer · target HER2 · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$505M
Runway
3.4 yrs
Shares 1y
+27%
Price & events
-57.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
+2.3%
1W
+7.6%
1M
-26.2%
3M
-55.1%
6M
+143.1%
1Y
-25.4%
2Y
-56.1%
5Y
-75.2%
All
Overview
- Market Cap
- $989.65M
- Volume
- 60.58K
- 52 Week Range
- $4.41 – $35.83
- Total Shares
- 87.35M
- Float Shares
- 64.18M
- Short %
- 19.52%
- % Held by Insiders
- 1.80%
- % Held by Institutions
- 119.34%
- RVOL
- 0.04x
- Beta
- 2.01
Pipeline stages · 2 programs
OP-3136, Fulvestrant, Palazestrant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Palazestrant, Ribociclib, Letrozole
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-05-30 Estimated 50% readout ~2027-06-29 | Phase 1 | OP-3136, Fulvestrant, Palazestrant | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant | — | recruiting |
| 2027-12-31 Estimated 50% readout ~2028-01-30 | Phase 1 | Palazestrant, Ribociclib, Alpelisibfast track | Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-02-14 | Phase 3 | Palazestrant, Ribociclib, Letrozolefast track | Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma | — | recruiting |
| 2026-06-30 | Phase 3 | Palazestrant, Fulvestrant, Anastrozolefast track | Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma | 510 | recruiting |
| 2026-03 | Phase 1 | Palazestrant, Palbociclibfast track | Breast Cancer | 60 | active not recruiting |
Catalyst news & presentations · 22
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)palazestrant · NDA submission for monotherapy in 2/3L metastatic breast cancerSEC 8-K
- 2026Guided 40%readoutPhase 1OP-3136 · Report initial clinical results for OP-3136.SEC 8-K
- second half of 2026Guided 55%readoutPhase 3palazestrant · Top-line data from OPERA-01.SEC 8-K
- H2 2026Guided 55%trial initiationsecondaryPhase 1/2OP-3136 · Phase 1b/2 study of OP-3136 plus darolutamide in ~36 patientsSEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- May 30, 2026conferencedata presentationsecondaryPhase 1OP-3136 · Poster presentation of initial Phase 1 data at ASCO 2026SEC 8-K
- May 30, 2026conferencedata presentationsecondaryPhase 3palazestrant · Trial-in-progress poster for Phase 3 OPERA-02 of palazestrant plus ribociclibSEC 8-K
- 2026-05-26partnershipOP-3136 · Clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 plus darolutamide in mCRPCSEC 8-K
- 2025trial initiationsecondaryPhase 3palazestrant · Potential initiation of OPERA-02 (palazestrant + ribociclib)SEC 8-K
- 2025trial initiationsecondaryPhase 1OP-3136 · Phase 1/2 clinical study to beginSEC 8-K
- 2025-11-18withdrawalTerminated ATM prospectus for common stock salesSEC 8-K
- October 20, 2025conferencedata presentationsecondaryPhase 1/2palazestrant · Poster presentation at ESMO 2025 of Phase 1b/2 data for palazestrant plus ribociclib.SEC 8-K
- ESMO 2025conferencedata presentationsecondaryPhase 1/2palazestrant · Present mature data from Phase 1b/2 study of palazestrant in combination with ribociclib.SEC 8-K
- Q3 2025trial initiationsecondaryPhase 3palazestrant · Initiate OPERA-02 trial of palazestrant in combination with ribociclib.SEC 8-K
- 2025-09-02partnershippalazestrant · Clinical trial collaboration with Pfizer to evaluate palazestrant plus atirmociclibSEC 8-K
- mid-2025trial initiationsecondaryPhase 1/2OP-3136 · Initiation of first-line combo with ribociclibSEC 8-K
- early 2025trial initiationsecondaryPhase 1OP-3136 · Phase 1 trial initiationSEC 8-K
- fourth quarter of 2024regulatory submissionFiled (NDA/BLA)OP-3136 · IND filing anticipatedSEC 8-K
- December 10-13, 2024conferencedata presentationsecondaryPhase 1/2palazestrant · Presentation of updated Phase 1b/2 data at SABCSSEC 8-K
- 2024-12-09fda agreementOP-3136 · FDA cleared IND for OP-3136SEC 8-K
- 2024-11-29partnershippalazestrant · Clinical trial collaboration and supply agreement with Novartis for ribociclib supply in planned Phase 3 OPERA-02 trial of palazestrant plus ribociclib in ER+/HER2- frontline advanced/metastatic breast cancer.SEC 8-K
- October 23-25, 2024conferencedata presentationsecondaryOP-3136 · Non-clinical data at EORTC-NCI-AACR SymposiumSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $41 (+259% upside) · 10 analysts
- 2026-05-13GuggenheimBuy
- 2026-03-27Wolfe ResearchPeer Perform
- 2026-03-18JP MorganOverweight
- 2026-03-18Goldman SachsBuy
- 2026-03-17CitigroupBuy
- 2026-03-17GuggenheimBuy
Competitors — HER2
Recent news
- 2026-07-23339,461 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by SEB Asset Management AB - MarketBeat
- 2026-07-21Jennison Associates LLC Has $27.17 Million Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
- 2026-07-17Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 5.9% - Here's Why - MarketBeat
- 2026-07-14Olema Pharmaceuticals (OLMA) Holds Above Support After Modest Upside Move - NHNL Divergence - dars.gov.et
- 2026-07-13LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
- 2026-07-12Wall Street Zen Upgrades Olema Pharmaceuticals (NASDAQ:OLMA) to "Sell" - MarketBeat
- 2026-07-10Price to earnings forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
- 2026-07-08Olema Pharmaceuticals (OLMA) Jefferies London Healthcare Conference 2025 Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.